CoreValve is experiencing swift adoption of its ReValving(R) System by leading European physicians due to its ease of percutaneous implantation
IRVINE, Calif. (PRWEB) January 3, 2008
Dr. Seguin's presentation, which is scheduled for 9:00 a.m. PST on Thursday, January 10, will update investors about CoreValve's progress toward clinical adoption of its breakthrough ReValving(R) System, which makes possible the replacement of an aortic heart valve via a non-surgical transcatheter approach.
"CoreValve is experiencing swift adoption of its ReValving(R) System by leading European physicians due to its ease of percutaneous implantation," said Dr. Seguin. "The procedure usually takes just one to two hours and is performed generally under local anesthesia in a cath lab setting. Initially, ReValving(R) is focused only on the highest-risk patients. However, there is a growing conviction among many in the medical community that ReValving(R) is indeed the procedure by which diseased aortic valves of less-sick patients will be treated in just three to five years."
CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving(R) System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving(R) System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based ReValving(R) System includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company's Web site at http://www.corevalve.com.
(Caution: the CoreValve ReValving(R) System will not be available in the USA for clinical trials or for sale until further notice.)